Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Production / Operations

Psyched downplays FDA's safety comments on AME-1

By The Northwire Desk — AI Analysis Oct 09, 2025 · 17:08 PSYC · 0.02 Psyched Wellness Ltd
PSYC · Price

Executive Summary

  • Completed an initial production run of the “Santa” dietary supplement shot on Sept. 15, 2025, with a soft launch planned for Oct. 1, 2025 and a second run scheduled for mid‑October.
  • Submitted a scaled‑up extraction process patent application (U.S. Application No. 19/157,676) on Aug. 18, 2025; the filing is now pending in the U.S. and Canada.
  • Voluntarily filed an NDIN with the FDA for AME‑1 in July 2025; although the FDA did not affirm safety, the company asserts compliance under the FFDCA and continues to market its products.

Key Details

  • Product Development:
  • “Santa” dietary supplement shot pilot run announced Apr. 10, 2025; initial production completed Sept. 15, 2025.

  • Soft launch targeted for Oct. 1, 2025; second production run slated for mid‑October to support holiday inventory.

  • Scientific Studies:

  • Genotoxicity study on AME‑1 started Mar. 14, 2025 (AMES test, in‑vitro TK‑MLA assay, micronucleus assay). Ongoing with results to be disclosed later.

  • Six‑month accelerated stability study by third‑party lab shows AME‑1 retains muscimol content up to 18 months and exhibits no microbial growth; product “Calm” now labeled with an 18‑month shelf life.

  • Patents:

  • Filed a “scaled‑up extraction process” patent application in the USPTO on Aug. 18, 2025 (U.S. Application No. 19/157,676).

  • Application pending in both United States and Canada.

  • Regulatory Update:

  • Submitted a New Dietary Ingredient Notification (NDIN) for AME‑1 to the FDA in July 2025, including historical use data and company‑conducted toxicology studies.

  • FDA response (Sept. 2025) indicated the filing did not demonstrate that AME‑1 “will reasonably be expected to be safe.” Company notes NDIN does not require FDA approval for market entry; compliance remains under FFDCA.

  • Market Expansion:

  • Company plans to grow route‑to‑market partnerships nationwide as additional AME‑1 products are introduced.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Psyched Wellness Ltd

Jun 10, 2026 · 17:16

Cash-burning micro‑cap supplement company faces leadership vacuum after CEO exit, with no safe‑harbor in sight.

Management Apr 23, 2026 · 07:31

Policy Tailwinds Mask Lingering FDA Safety Overhangs in Psyched Wellness

Other Mar 20, 2026 · 09:17

Psyched Wellness Announces Closing of Private Placement and Shares for Debt Transaction and Resignation of a Director

Financings Mar 11, 2026 · 08:55

Psyched Wellness Announces Private Placement for Proceeds of up to C$1,719,306.94

Financings Jan 15, 2026 · 12:43

Psyched Wellness Sells Out of First Run of Calmer and Announces New Production Run

Other Oct 09, 2025 · 07:31

Psyched Wellness Provides Comprehensive Investor Update

Production / Operations